Short Interest in VolitionRX Limited (NYSEAMERICAN:VNRX) Expands By 491.8%
by Teresa Graham · The Cerbat GemVolitionRX Limited (NYSEAMERICAN:VNRX – Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 8,074,406 shares, a growth of 491.8% from the March 15th total of 1,364,488 shares. Currently, 5.6% of the shares of the company are sold short. Based on an average daily volume of 47,461,105 shares, the short-interest ratio is presently 0.2 days.
VolitionRX Stock Performance
VNRX traded down $0.01 on Friday, reaching $0.17. The company had a trading volume of 3,714,146 shares, compared to its average volume of 29,939,412. VolitionRX has a fifty-two week low of $0.15 and a fifty-two week high of $0.94. The stock has a market cap of $26.28 million, a P/E ratio of -0.75 and a beta of 1.33. The company’s fifty day moving average is $0.21 and its 200 day moving average is $0.31.
VolitionRX (NYSEAMERICAN:VNRX – Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The medical research company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). The company had revenue of $0.45 million during the quarter, compared to analyst estimates of $0.71 million. On average, sell-side analysts expect that VolitionRX will post -0.5 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in VolitionRX in the 3rd quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. bought a new stake in VolitionRX in the 2nd quarter valued at about $52,000. Jane Street Group LLC bought a new stake in VolitionRX in the 4th quarter valued at about $28,000. Squarepoint Ops LLC bought a new stake in VolitionRX in the 4th quarter valued at about $34,000. Finally, Silverberg Bernstein Capital Management LLC boosted its holdings in VolitionRX by 15.6% in the 3rd quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the medical research company’s stock valued at $157,000 after purchasing an additional 31,300 shares during the period. Institutional investors and hedge funds own 8.09% of the company’s stock.
Analysts Set New Price Targets
Several research analysts have recently weighed in on the stock. HC Wainwright lowered their price objective on shares of VolitionRX from $1.50 to $1.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. D. Boral Capital restated a “buy” rating and set a $3.00 price objective on shares of VolitionRX in a research note on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $2.33.
Get Our Latest Report on VolitionRX
About VolitionRX
VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.
The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.